Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 12/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684699 | 0.86 | AOC3 (0.54) | AOC3CACNA1HSMN1; SMN2HPGDRAB9A | |
| SCHEMBL17316414 | 0.83 | AOC3 (0.54) | AOC3CACNA1H | |
| SCHEMBL17316325 | 0.80 | AOC3 (0.51) | AOC3CACNA1H | |
| SCHEMBL2806435 | 0.80 | AOC3 (0.59) | AOC3CACNA1HALDH1A1LMNA | |
| SCHEMBL30452503 | 0.79 | AOC3 (0.61) | AOC3CACNA1HKMT2AALDH1A1LMNA | |
| SCHEMBL2820792 | 0.78 | P2RY12 (0.64) | SMN1; SMN2HPGDRAB9ANPC1KDM4E | |
| SCHEMBL11872337 | 0.77 | MAPT (0.54) | SMN1; SMN2HPGDRAB9ANPC1KDM4E | |
| SCHEMBL17316306 | 0.77 | AOC3 (0.56) | AOC3CACNA1H | |
| SCHEMBL16661072 | 0.77 | PANK3 (0.57) | AOC3SMN1; SMN2HPGD | |
| SCHEMBL7469230 | 0.77 | P2RY12 (0.63) | SMN1; SMN2HPGDRAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | AOC3 256/4885CACNA1H 1524/4885SMN1; SMN2 4204/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | AOC3 221/4885CACNA1H 1663/4885SMN1; SMN2 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.